Meeting
2022 ASCO Annual Meeting
SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC).
Authors
Toni K. Choueiri
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
Toni K. Choueiri , Wanning Xu , Lynne Poole , Aino Telaranta-Keerie , Ryan Hartmaier , Thomas Powles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT05043090
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4601)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4601
Abstract #
TPS4601
Poster Bd #
90b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).
First Author: Matt D. Galsky
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
First Author: Thomas Powles
Poster
2020 ASCO Virtual Scientific Program
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.
First Author: Konrad Friedrich Klinghammer